Zou Yifei, Song Xianjing, Liu Ning, Sun Wei, Liu Bin
Department of Cardiology, The Second Hospital of Jilin University, Changchun, China.
Aging Dis. 2022 Jun 1;13(3):753-772. doi: 10.14336/AD.2021.1022. eCollection 2022 Jun.
Although substantial progress has been made in reducing the burden of the disease by preventing the risk factors of cardiovascular disease (CVD), potential risk factors still exist and lead to its progression. In recent years, numerous studies have revealed that intestinal flora can interfere with the physiological processes of the host through changes in composition and function or related metabolites. Intestinal flora thus affects the occurrence and development of a variety of CVDs, including atherosclerosis, ischemic heart disease, and heart failure. Moreover, studies have found that interventions for intestinal flora and its metabolites provide new opportunities for CVD treatment. This article mainly discusses the interaction between the human intestinal flora and its metabolites, the occurrence and development of CVD, and the potential of intestinal flora as a new target for the diagnosis and treatment of CVD.
尽管通过预防心血管疾病(CVD)的危险因素在减轻该疾病负担方面已取得重大进展,但潜在危险因素仍然存在并导致其进展。近年来,大量研究表明,肠道菌群可通过组成和功能或相关代谢产物的变化干扰宿主的生理过程。因此,肠道菌群会影响包括动脉粥样硬化、缺血性心脏病和心力衰竭在内的多种心血管疾病的发生和发展。此外,研究发现对肠道菌群及其代谢产物的干预为心血管疾病的治疗提供了新机会。本文主要讨论人类肠道菌群与其代谢产物之间的相互作用、心血管疾病的发生和发展,以及肠道菌群作为心血管疾病诊断和治疗新靶点的潜力。